In his first interaction with the media (the first part of which was published on Sunday) since the drug maker pleaded guilty of making fraudulent statements to the US Food and Drugs Administration under its previous management and agreed to pay a hefty $500-million penalty, Ranbaxy CEO & MD Arun Sawhney told Business Standard: “We instituted a whistle-blower policy sometime back. We are constantly encouraging that. Here, the employees are encouraged to draw the attention of the management (where required).”
According to him, the company even encourages anonymous mails from its employees as part of the policy.
The move is significant in the light of the recent developments in the US following a whistle-blower’s disclosure. Dinesh Thakur, a former Ranbaxy employee and a whistle-blower in this case, in his testimony to the US District Court of Maryland had alleged his boss, Rajinder Kumar, then head of R&D at Ranbaxy, had informed the then senior management of the company about the ongoing fraudulent practices in the company.
Thakur worked in Ranbaxy from June 2003 to April 2005.
Sawhney declined to address questions that came under the purview of the former or the current shareholders but assured what had happened in the past would not be repeated in the future because the company had taken all required steps to address those concerns internally.
“It is not only about profit but also about patient safety and quality for us. That will be the guidance. Never in future should there be a question on our compliance or quality… This is what I want the new culture of Ranbaxy to be built on,”
Meet the youngest Indian to climb Mount Everest
End of the race for Mahalaxmi Race Course?
UB Group takes lenders to court
'IPL spot-fixing saga won't affect cricket's popularity'
PIX: When Deepika, Kareena, Ash wore spectacles!